107 related articles for article (PubMed ID: 29894066)
1. The antibody-based CA125-targeted maintenance therapy for the epithelial ovarian cancer: a meta-analysis.
Mei L; Hou Q; Fang F; Wang H
Eur J Gynaecol Oncol; 2016 Aug; 37(4):455-460. PubMed ID: 29894066
[TBL] [Abstract][Full Text] [Related]
2. Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival-a substudy of the MIMOSA trial.
Buzzonetti A; Fossati M; Catzola V; Scambia G; Fattorossi A; Battaglia A
Cancer Immunol Immunother; 2014 Oct; 63(10):1037-45. PubMed ID: 24952307
[TBL] [Abstract][Full Text] [Related]
3. Maintenance chemotherapy for ovarian cancer.
Mei L; Chen H; Wei DM; Fang F; Liu GJ; Xie HY; Wang X; Zou J; Han X; Feng D
Cochrane Database Syst Rev; 2010 Sep; (9):CD007414. PubMed ID: 20824860
[TBL] [Abstract][Full Text] [Related]
4. Clinical Significance of CA125 Level after the First Cycle of Chemotherapy on Survival of Patients with Advanced Ovarian Cancer.
Lee M; Chang MY; Yoo H; Lee KE; Chay DB; Cho H; Kim S; Kim YT; Kim JH
Yonsei Med J; 2016 May; 57(3):580-7. PubMed ID: 26996555
[TBL] [Abstract][Full Text] [Related]
5. Front-line chemoimmunotherapy for treating epithelial ovarian cancer: Part II promising results of phase 2 study of paclitaxel-carboplatin-oregovomab regimen.
Yang ST; Chang WH; Chou FW; Liu HH; Lee WL; Wang PH
Taiwan J Obstet Gynecol; 2024 Jan; 63(1):10-16. PubMed ID: 38216242
[TBL] [Abstract][Full Text] [Related]
6. A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer.
Ehlen TG; Hoskins PJ; Miller D; Whiteside TL; Nicodemus CF; Schultes BC; Swenerton KD
Int J Gynecol Cancer; 2005; 15(6):1023-34. PubMed ID: 16343178
[TBL] [Abstract][Full Text] [Related]
7. Antigen-specific active immunotherapy for ovarian cancer.
Leffers N; Daemen T; Helfrich W; Boezen HM; Cohlen BJ; Melief CJ; Nijman HW
Cochrane Database Syst Rev; 2014 Sep; (9):CD007287. PubMed ID: 25229990
[TBL] [Abstract][Full Text] [Related]
8. Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials.
Vidal L; Gafter-Gvili A; Leibovici L; Dreyling M; Ghielmini M; Hsu Schmitz SF; Cohen A; Shpilberg O
J Natl Cancer Inst; 2009 Feb; 101(4):248-55. PubMed ID: 19211444
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value and Implication for Chemotherapy Treatment of ABCB1 in Epithelial Ovarian Cancer: A Meta-Analysis.
Sun S; Cai J; Yang Q; Zhu Y; Zhao S; Wang Z
PLoS One; 2016; 11(11):e0166058. PubMed ID: 27812204
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Dhillon S
BioDrugs; 2013 Aug; 27(4):375-92. PubMed ID: 23728884
[TBL] [Abstract][Full Text] [Related]
11. Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy.
Azad NS; Annunziata CM; Steinberg SM; Minasian L; Premkumar A; Chow C; Kotz HL; Kohn EC
Cancer; 2008 Apr; 112(8):1726-32. PubMed ID: 18300236
[TBL] [Abstract][Full Text] [Related]
12. Postoperative human epididymis protein 4 predicts primary therapy outcome in advanced epithelial ovarian cancer.
Vallius T; Hynninen J; Auranen A; Matomäki J; Oksa S; Roering P; Grènman S
Tumour Biol; 2017 Feb; 39(2):1010428317691189. PubMed ID: 28218038
[TBL] [Abstract][Full Text] [Related]
13. Monitoring ovarian cancer patients during chemotherapy and follow-up with the serum tumor marker CA125.
Abu Hassaan SO
Dan Med J; 2018 Apr; 65(4):. PubMed ID: 29619933
[TBL] [Abstract][Full Text] [Related]
14. The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study.
Nassir M; Guan J; Luketina H; Siepmann T; Rohr I; Richter R; Castillo-Tong DC; Zeillinger R; Vergote I; Van Nieuwenhuysen E; Concin N; Marth C; Hall C; Mahner S; Woelber L; Sehouli J; Braicu EI
Tumour Biol; 2016 Mar; 37(3):3009-16. PubMed ID: 26419591
[TBL] [Abstract][Full Text] [Related]
15. Difference in mesothelin-binding ability of serum CA125 between patients with endometriosis and epithelial ovarian cancer.
Sasaki A; Akita K; Ito F; Mori T; Kitawaki J; Nakada H
Int J Cancer; 2015 Apr; 136(8):1985-90. PubMed ID: 25197000
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and toxicity of bevacizumab in recurrent ovarian disease: an update meta-analysis on phase III trials.
Marchetti C; De Felice F; Palaia I; Musella A; Di Donato V; Gasparri ML; Musio D; Muzii L; Tombolini V; Panici PB
Oncotarget; 2016 Mar; 7(11):13221-7. PubMed ID: 26657509
[TBL] [Abstract][Full Text] [Related]
17. Interval debulking surgery for advanced epithelial ovarian cancer.
Tangjitgamol S; Manusirivithaya S; Laopaiboon M; Lumbiganon P; Bryant A
Cochrane Database Syst Rev; 2010 Oct; (10):CD006014. PubMed ID: 20927744
[TBL] [Abstract][Full Text] [Related]
18. Follow-up with CA125 after primary therapy of advanced ovarian cancer has major implications for treatment outcome and trial performances and should not be routinely performed.
Rustin GJ
Ann Oncol; 2011 Dec; 22 Suppl 8():viii45-viii48. PubMed ID: 22180399
[TBL] [Abstract][Full Text] [Related]
19. Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer.
Grisham RN; Berek J; Pfisterer J; Sabbatini P
Immunotherapy; 2011 Feb; 3(2):153-62. PubMed ID: 21322756
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.
Winter-Roach BA; Kitchener HC; Dickinson HO
Cochrane Database Syst Rev; 2009 Jul; (3):CD004706. PubMed ID: 19588360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]